<DOC>
	<DOCNO>NCT02321839</DOCNO>
	<brief_summary>To evaluate visual outcome , number injection visit , effect mental status treat extend regimen manage neovascular age-related macular degeneration intravitreal ranibizumab .</brief_summary>
	<brief_title>Evaluation Usefulness Treat Extend Regimen Using Ranibizumab Neovascular AMD .</brief_title>
	<detailed_description>Treat Extend Regimen ( TER ) may contribute improvement patient ' mentality , since treatment interval extend sign recurrence . Therefore , plan examine psychological impact TER use Hospital Anxiety Depression Scale ( HADS ) , addition improvement visual acuity central retinal thickness .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent form Male female age 50 year old Typical AMD PCV patient BCVA 24 letter Total lesion area ＞12 DA ＞30.5 mm2 The existence subretinal hemorrhage area constitute ≥50 % total lesion area The existence scar fibrosis area constitute ≥50 % total lesion area The existence RPE tear Prior treatment wet AMD History vitrectomy surgery , submacular surgery , surgical intervention AMD The pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>neovascular age-related macular degeneration</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Treat extend</keyword>
</DOC>